You are here

NAJIT TECHNOLOGIES INC

Company Information
Address
15232 NW GREENBRIER PKWY
BEAVERTON, OR 97006-5764
United States



Information

UEI: MHB6EFN66MD9

# of Employees: N/A


Ownership Information

HUBZone Owned: No

Socially and Economically Disadvantaged: No

Woman Owned: No



Award Charts




Award Listing

  1. Development of an improved intranasal vaccine against influenza

    Amount: $275,107.00

    Despite the development of several types of influenza vaccines (live-attenuated, inactivated, subunit), the World Health Organization estimates that seasonal influenza is still responsible for 3-5 mil ...

    STTRPhase I2022Department of Health and Human Services National Institutes of Health
  2. A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine

    Amount: $1,997,314.00

    Abstract Yellow fever virus (YFV) is a mosquito-borne emerging/re-emerging hemorrhagic fever virus that causes 20- 60% mortality and is endemic in rt40 countries. The current live attenuated YFV vacci ...

    SBIRPhase II2021Department of Health and Human Services National Institutes of Health
  3. A Randomized Phase I Clinical Trial of HydroVax-CHIKV, a Novel Inactivated Chikungunya Virus Vaccine

    Amount: $290,420.00

    Chikungunya virus (CHIKV) is an alphavirus that has gained significant attention due to its ability to cause large epidemics among susceptible populations and to be spread beyond endemic countries by ...

    SBIRPhase I2020Department of Health and Human Services National Institutes of Health
  4. A Randomized Phase I Clinical Trial of HydroVax-YFV, a Novel Inativated Yellow Fever Vaccine

    Amount: $292,140.00

    Yellow fever virusYFVis a mosquito borne emerging re emerging hemorrhagic fever virus that causesmortality and is endemic in andgtcountriesThe current live attenuated YFV vaccine was developed inand h ...

    SBIRPhase I2019Department of Health and Human Services National Institutes of Health
  5. Optimization of vaccine antigen for the development of improved influenza

    Amount: $224,171.00

    Optimization of vaccine antigen for the development of improved influenza vaccines ABSTRACT Despite over years of vaccine development influenza remains a persistent global challenge for public health ...

    SBIRPhase I2019Department of Health and Human Services Centers for Disease Control and Prevention
  6. Development of a Yellow Fever Vaccine for a Vulnerable Population

    Amount: $3,242,503.00

    ABSTRACT Yellow fever virus (YFV) represents a mosquito-borne emerging/re-emerging human pathogen that causes 20- 50% mortality and is endemic in andgt;40 countries. The current live attenuated YFV va ...

    SBIRPhase II2018Department of Health and Human Services National Institutes of Health
  7. Development of an H2O2-inactivated chikungunya virus vaccine

    Amount: $2,983,602.00

    Chikungunya virusCHIKVis an alphavirus that has gained significant attention due to its ability to cause large epidemics among susceptible populations and to be spread beyond endemic countries by inte ...

    SBIRPhase II2017Department of Health and Human Services National Institutes of Health
  8. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    Amount: $318,591.00

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking ...

    STTRPhase I2016Department of Health and Human Services National Institutes of Health
  9. Development of a Yellow Fever Vaccine for Vulnerable Population

    Amount: $2,986,707.00

    DESCRIPTION (provided by applicant): Yellow fever virus (YFV) was at one time endemic in the United States and represents a mosquito-borne emerging/re-emerging human pathogen that causes up to 20% mor ...

    SBIRPhase II2011Department of Health and Human Services National Institutes of Health
  10. Development of a Yellow Fever Vaccine for Vulnerable Populations

    Amount: $585,202.00

    DESCRIPTION (provided by applicant): Yellow fever virus (YFV) was at one time endemic in the United States and represents an emerging/re-emerging human pathogen that causes up to 20% mortality. Althou ...

    SBIRPhase I2008Department of Health and Human Services National Institutes of Health
US Flag An Official Website of the United States Government